Zhongyi Zhu , Lei Zhang , Shuangbao Li , Yang Gao , Yuwei Wang , Xiaofei Ma , Zhonglin Chen , Siyu Wu , Yonghui Zhang , Mengyuan Zhang , Zhihao Xie , Changcheng Yin , Weijun Chen , Fuxing Zeng , Jinmin Ma
{"title":"在较低剂量的 COVID-19 mRNA 疫苗中，S-6P 的免疫原性优于 S-2P","authors":"Zhongyi Zhu , Lei Zhang , Shuangbao Li , Yang Gao , Yuwei Wang , Xiaofei Ma , Zhonglin Chen , Siyu Wu , Yonghui Zhang , Mengyuan Zhang , Zhihao Xie , Changcheng Yin , Weijun Chen , Fuxing Zeng , Jinmin Ma","doi":"10.1016/j.dcit.2024.100017","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>The objective of this study was to determine whether a new combination of immunogens could be more effective than the S–2P design in terms of eliciting an immune response. The study aimed to use a unified formulation standard to make a comparison between the new immunogen combination than the S–2P design.</p></div><div><h3>Methods</h3><p>The study analyzed the published immunogen mutation strategies of known COVID-19 vaccines and also Spike protein variants in the RCSB database to identify the most promising immunogen combination. By choosing different Spike protein variants, we prepared well characterized mRNA preparations and administered them to BALB/C mice using a commercial lipid for encapsulation.</p></div><div><h3>Results</h3><p>The study found that our mRNA preparations stimulated strong humoral and cellular immunity, with a neutralizing antibody titer of >1*10<sup>4</sup> at 28 days and a Th1-biased cellular immune response. Furthermore, our results indicate that the S–6P-GSAS variant elicits superior immunogenicity at lower doses compared to the S–2P variant.</p></div><div><h3>Conclusion</h3><p>Our study suggests that the S–6P-GSAS variant may elicit a stronger immune response at lower doses compared to the S–2P design, indicating its potential as a promising immunogen candidate for COVID-19 vaccines. Further research is needed to explore the efficacy of this novel combination in addressing the challenges posed by emerging Spike protein variants.</p></div>","PeriodicalId":100358,"journal":{"name":"Decoding Infection and Transmission","volume":"2 ","pages":"Article 100017"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949924024000016/pdfft?md5=08289a1424f0e2c2817dc353af88ff06&pid=1-s2.0-S2949924024000016-main.pdf","citationCount":"0","resultStr":"{\"title\":\"S–6P exhibits better immunogenicity than S–2P at lower doses of COVID-19 mRNA vaccines\",\"authors\":\"Zhongyi Zhu , Lei Zhang , Shuangbao Li , Yang Gao , Yuwei Wang , Xiaofei Ma , Zhonglin Chen , Siyu Wu , Yonghui Zhang , Mengyuan Zhang , Zhihao Xie , Changcheng Yin , Weijun Chen , Fuxing Zeng , Jinmin Ma\",\"doi\":\"10.1016/j.dcit.2024.100017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>The objective of this study was to determine whether a new combination of immunogens could be more effective than the S–2P design in terms of eliciting an immune response. The study aimed to use a unified formulation standard to make a comparison between the new immunogen combination than the S–2P design.</p></div><div><h3>Methods</h3><p>The study analyzed the published immunogen mutation strategies of known COVID-19 vaccines and also Spike protein variants in the RCSB database to identify the most promising immunogen combination. By choosing different Spike protein variants, we prepared well characterized mRNA preparations and administered them to BALB/C mice using a commercial lipid for encapsulation.</p></div><div><h3>Results</h3><p>The study found that our mRNA preparations stimulated strong humoral and cellular immunity, with a neutralizing antibody titer of >1*10<sup>4</sup> at 28 days and a Th1-biased cellular immune response. Furthermore, our results indicate that the S–6P-GSAS variant elicits superior immunogenicity at lower doses compared to the S–2P variant.</p></div><div><h3>Conclusion</h3><p>Our study suggests that the S–6P-GSAS variant may elicit a stronger immune response at lower doses compared to the S–2P design, indicating its potential as a promising immunogen candidate for COVID-19 vaccines. Further research is needed to explore the efficacy of this novel combination in addressing the challenges posed by emerging Spike protein variants.</p></div>\",\"PeriodicalId\":100358,\"journal\":{\"name\":\"Decoding Infection and Transmission\",\"volume\":\"2 \",\"pages\":\"Article 100017\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949924024000016/pdfft?md5=08289a1424f0e2c2817dc353af88ff06&pid=1-s2.0-S2949924024000016-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Decoding Infection and Transmission\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949924024000016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Decoding Infection and Transmission","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949924024000016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
S–6P exhibits better immunogenicity than S–2P at lower doses of COVID-19 mRNA vaccines
Objective
The objective of this study was to determine whether a new combination of immunogens could be more effective than the S–2P design in terms of eliciting an immune response. The study aimed to use a unified formulation standard to make a comparison between the new immunogen combination than the S–2P design.
Methods
The study analyzed the published immunogen mutation strategies of known COVID-19 vaccines and also Spike protein variants in the RCSB database to identify the most promising immunogen combination. By choosing different Spike protein variants, we prepared well characterized mRNA preparations and administered them to BALB/C mice using a commercial lipid for encapsulation.
Results
The study found that our mRNA preparations stimulated strong humoral and cellular immunity, with a neutralizing antibody titer of >1*104 at 28 days and a Th1-biased cellular immune response. Furthermore, our results indicate that the S–6P-GSAS variant elicits superior immunogenicity at lower doses compared to the S–2P variant.
Conclusion
Our study suggests that the S–6P-GSAS variant may elicit a stronger immune response at lower doses compared to the S–2P design, indicating its potential as a promising immunogen candidate for COVID-19 vaccines. Further research is needed to explore the efficacy of this novel combination in addressing the challenges posed by emerging Spike protein variants.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
